Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - NETs and endocrine tumours

2800 - Efficacy of Lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)


22 Oct 2018


Proffered paper session - NETs and endocrine tumours


Cytotoxic Therapy

Tumour Site

Neuroendocrine Neoplasms


Jaume Capdevila Castillon


Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293


J. Capdevila Castillon1, N. Fazio2, C. Lopez3, A. Teule4, J.W. Valle5, S. Tafuto6, A. Custodio7, N. Reed8, M. Raderer9, E. Grande10, R. Garcia-Carbonero11, P. Jimenez Fonseca12, V. Alonso13, L. Antonuzzo14, A. Spallanzani15, A. Berruti16, I. Sevilla Garcia17, A. La Casta18, J. Hernando1, T. Ibrahim19

Author affiliations

  • 1 Gastrointestinal And Endocrine Tumor Unit, Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 2 Unit Of Gastrointestinal Medical Oncology And Neuroendocrine Tumors, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 3 Medical Oncology, Marques de Valdecilla University Hospital, Santander/ES
  • 4 Medical Oncology, Catalan Institute of Oncology (ICO), 8026 - Bellvitge/ES
  • 5 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 6 Medical Oncology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 7 Medical Oncology Department, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 8 Medical Oncology, Beatson West of Scotland Cancer Centre, G12 0YN - Glasgow/GB
  • 9 Medical Oncology, Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT
  • 10 Head Of Medical Oncology Department, MD Anderson Cancer Center Center Espana, 28033 - Madrid/ES
  • 11 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 12 Medical Oncology, Hospital Universitario Central de Asturias, 33006 - Oviedo/ES
  • 13 Medical Oncology Service, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 14 Medical Oncology Service, Azienda Ospedaliera Careggi, 50139 - Firenze/IT
  • 15 Medical Oncology, University Hospital of Modena, Modena/IT
  • 16 Department Of Medical And Surgical Specialties, Radiological Sciences, And Publi, Azienda Ospedaliera Spedali Civili di Brescia, 25123 - Brescia/IT
  • 17 Medical Oncology Service, Hospital Regional Universitario Carlos Haya, 29010 - Malaga/ES
  • 18 Medical Oncology, Donosti University Hospital, Donosti/ES
  • 19 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2800


Patients (pts) with advanced well-differentiated (G1/G2) NETs have limited treatment options. Everolimus (E) and sunitinib (S) are approved with overall response rates (ORR) <10% with no demonstrated activity after progression (PD) to prior targeted agents (TA). Lenvatinib is a multikinase inhibitor with potent affinity against VEGFR1-3 and FGFR1-4 that may increase efficacy and revert primary and acquired resistance to TA. We conducted a phase II study to evaluate the efficacy of lenvatinib in panNETS and giNETs.


This is a prospective phase II study with two cohorts of pts with advanced G1/G2 panNETs (cohort A) and giNETs (cohort B). All pts had documented PD by RECIST prior inclusion. In cohort A, pts should have PD to E or S, regardless prior therapy with somatostatin analogs (SSAs) or chemotherapy (CHT), and in cohort B after PD on SSAs. Pts were treated with lenvatinib at 24 mg qd until PD or intolerable toxicity. The primary endpoint was ORR by RECIST 1.1 upon central radiology review. With 55 pts in each arm, our study was powered to identify an ORR with lenvatinib of ≥ 25% with 90% power and 5% α-error.


We included 111 pts (55 panNETs and 56 giNETs). Median age was 59-y, 51% were male and 70% were G2. For panNETs, 32% of pts were previously treated with CHT, 87% with SSAs, 70% with E and 30% with S. ORR by central radiology assessment was 29%, 40% for panNETs and 18.5% for giNETs. Stable disease was observed as best response in 55.7% of panNETs and 76% of giNETs. With a median follow-up of 11 months, estimated median progression-free survival (PFS) for panNETs was 14.2 months (95% CI 11.4-NR) and 17.6 months (95% CI 11.5-NR) for giNETs. Adverse events (AEs) were mild to moderate in 90% of pts, being fatigue, diarrhea and hypertension the most frequent. Grade 3/4 AEs were reported in 10% of pts.


Lenvatinib showed significant antitumor activity and a favorable toxicity profile in progressive advanced NETs. This is the highest reported ORR with a TA confirmed by central radiology assessment in panNETs and giNETs with promising PFS in a pretreated population; further evaluation is warranted.

Clinical trial identification


Legal entity responsible for the study

Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE).



Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.